Migraine With Aura
86
13
15
42
Key Insights
Highlights
Success Rate
86% trial completion
Published Results
12 trials with published results (14%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
8.1%
7 terminated out of 86 trials
85.7%
-0.8% vs benchmark
19%
16 trials in Phase 3/4
29%
12 of 42 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 42 completed trials
Clinical Trials (86)
Responding With Evidence and Access for Childhood Headaches
Migraine Attack Pain Phase Prediction Study
A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department
Mind Body Balance for Pediatric Migraine
A Comprehensive Digital Care Program for Migraine Management
Effectiveness and Tolerability of Eptinezumab
RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment
Using Virtual Reality to Teach Mindfulness to People With Migraine
Trial Designs for Evaluating Migraine Treatment
Neurogenetic And Hemodynamic Of Migraine Aura And Pfo
The Sequestration of Holistic Stress Management Techniques for Adults
App-Based Migraine Treatment: The Health enSuite Study
Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients
Gepant treAtments: EffectIveNess and tolERability (GAINER)
Ditan Acute tReatments: Effectiveness and Tolerability (DART)
Induction of Migraine Attacks With Aura Using Pituitary Adenylate Cyclase Activating Polypeptide-38
Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura
Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine
Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room
Migraine With and Without Aura Characteristics and Response to Remote Electrical Neuromodulation (REN) Treatment